View Older Stories View More Recent Stories
-
Moderna CMV vaccine fails phase 3 trial, development discontinued
-
Moderna Announces Phase 3 Study of Investigational Cytomegalovirus (CMV) Vaccine Did Not Meet Primary Efficacy Endpoint
-
Needham Reiterates Hold Rating on Moderna (MRNA)
-
Moderna Highlights Seasonal Flu and H5 Pandemic Flu Candidates at IDWeek 2025
-
Moderna to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025
-
Moderna reports early cancer therapy data at medical conference
-
Moderna Presents Promising Early Data for Its Investigational Cancer Antigen Therapy at the 2025 European Society for Medical Oncology Congress
-
Acting CDC head Jim O’neill: I call on vaccine manufacturers to develop safe monovalent vaccines to replace the combined MMR - X post
-
Moderna (MRNA) call put ratio 9.5 calls to 1 put with a focus on October 3 weekly and October 10 weekly 10 calls
-
Bernstein on AmericasMedicines.com: 'The Noise Starts, But Not (Yet) from Trump'
-
Rfk Jr. Weighs Expansion Of Vaccine Injury Program: Adviser - Bloomberg
-
Moderna Opens State-of-the-Art Manufacturing and R&D Facility in the UK
-
Brookline: 'We currently estimate that 2025 Moderna COVID-19 vaccine sales will include 10.9 million doses in the US'
-
Moderna vaccine shows strong immune response against LP.8.1 variant
-
Moderna Announces mNEXSPIKE Generates Strong Immune Response Against LP.8.1 Variant in Humans
-
CDC Panel Votes Against Requiring Prescriptions For Covid Shots - Bloomberg
-
CDC Panel Votes To End Universal Recommendation For Covid Shots - Bloomberg
-
Kennedy To Change Childhood Vaccine Schedule In Sept: Monarez - Bloomberg
-
UBS Reiterates Buy Rating on Moderna (MRNA) as Drastic Change to COVID-19 Vaccine Access Appears Unlikely
-
Moderna COVID-19 vaccine shows 8-fold antibody increase against LP.8.1 variant
-
Moderna Announces Updated COVID-19 Vaccine Against LP.8.1 Variant Generates Strong Immune Response in Humans
-
Moderna reinforces that there are no new safety concerns for Spikevax vaccine
-
Moderna (MRNA) call put ratio 2.6 calls to 1 put, share price down 6.7%
-
Pfizer, Moderna, BioNTech trade lower amid report of vaccine link to child deaths
-
US officials plan to link 25 child deaths to covid shots - WaPo
-
RBC Capital on Biotech: 'Who Wins and Who Loses If RFK, Jr. Goes'
-
Rfk Jr. Moves To Add More Hand-picked Vaccine Advisory Members - Bloomberg
-
Moderna to present rare disease data at metabolism congress
-
Moderna Announces Data to be Presented at the 2025 International Congress of Inborn Errors of Metabolism
-
White House Taps Top RFK Jr. Deputy As Acting CDC Director - Washington Post
-
CDC Director Monarez Is Being Ousted - WAPO
-
Moderna receives FDA approval for updated COVID-19 vaccines
-
Moderna Receives U.S. FDA Approval for Updated COVID-19 Vaccines Targeting LP.8.1 Variant of SARS-CoV-2
-
FDA Authorizes Covid Vaccines For Those At Higher Risk - Kennedy
-
Health Canada approves Moderna COVID-19 vaccine targeting LP.8.1 variant
-
Moderna to Present at Upcoming Conferences in September 2025
-
Bernstein on Moderna (MRNA): 'Still a Long Road to Profitability'
-
UBS Reiterates Buy Rating on Moderna (MRNA)
-
Moderna (MRNA) PT Lowered to $24 at BofA Securities
-
Moderna (MRNA) PT Lowered to $18 at Leerink Partners
-
Moderna (MRNA) PT Lowered to $25 at TD Cowen
-
Moderna (MRNA) Tops Q2 EPS by 85c; offers guidance
-
Moderna Reports Second Quarter 2025 Financial Results and Provides Business Updates
-
Moderna (MRNA) says UK Court of Appeal has upheld the validity of Moderna's EP'949 patent
-
UK Court of Appeal Confirms Moderna’s EP'949 Patent is Valid and Infringed by Pfizer/BioNTech
-
Moderna earnings preview Q2: set for weak qtr amid softer vaccine sales, regulatory headwinds
-
Moderna (MRNA) call put ratio 1 call to 1 put into quarter results
-
Moderna (MRNA) call put ratio 1.6 calls to 1 put into quarter results
-
Moderna receives European approval for updated COVID-19 vaccine
-
Moderna Receives European Commission Approval for Updated COVID-19 Vaccine Targeting SARS-CoV-2 Variant LP.8.1
